Long non-coding RNAs (lncRNAs) have emerged as potential biomarkers since aberrant expression has been reported in bladder cancer, some upregulated (lncRNA urothelial cancer associated 1 and lncRNA metastasis-associated lung adenocarcinoma transcript 1) (Wang et al., 2008; Han et al., 2013), and others downregulated such as maternally expressed 3 (MEG3) (Ying et al., 2013). This evidence concerns the gene MEG3 and urinary bladder cancer.